Welcome to the e-CCO Library Archive!

Filter:

DOP039

Point-of-care monitoring of infliximab trough levels in capillary fingerstick blood of patients with inflammatory bowel disease (IBD)

Authors:

J. Maljaars*1, C. de Dood2, S. van der Burg1, A. van der Meulen1, H. Tanke2, P. Corstjens2

1LUMC, Gastroenterology-Hepatology, Leiden, Netherlands, 2Leiden University Medical Centre, Department of Molecular Cell Biology Geb. 1, Leiden, Netherlands

DOP040

Effects of education and information on vaccination behaviour in IBD patients

Authors:

S. Coenen*1, E. Weyts1, C. Jorissen2, P. De Munter3, M. Noman1, V. Ballet1, S. Vermeire1, G. Van Assche1, M. Ferrante1

1UZ Leuven, Gastroenterology, Leuven, Belgium, 2KU Leuven, Leuven, Belgium, 3UZ Leuven, Leuven, Belgium

DOP041

Impact of an education programme on IBD patients skills: one year results of the ECIPE randomised, controlled multicentre study.

Authors:

J. Moreau1, L. Marthey2, C. Trang3, M. Nachury4, R. Altwegg5, J.-C. Grimaud6, S. Orempuller1, J. Filippi7, A. Aubourg8, C. Baudry9, P. Seksik10, X. Roblin11, S. Nahon12, G. Savoye13, B. Mesnard14, C. Stefanescu15, M. Simon16, B. Coffin17, J.-L. Dupas18, S. Chevret19, M. Allez*20

1Rangueil Hospital, Department of Gastroenterology, Toulouse, France, 2Bicetre Hospital, Department of Gastroenterology, Le Kremlin Bicêtre, France, 3CHU Hotel Dieu, Department of Gastroenterology, Nantes, France, 4Huriez Hospital, Department of Gastroenterology, Lille, France, 5Saint Eloi Hospital, Department of Hepatology and Gastroenterology, Montpellier, France, 6Nord Hospital, Department of Gastroenterology, Marseille, France, 7Archet Hospital, Department of Gastroenterology and Nutrition, Nice, France, 8Trousseau University Hospital, Department of Gastroenterology, Tours, France, 9Saint-Louis Hospital, Department of Gastroenterology and Hepatology, Paris, France, 10St. Antoine Hospital, Department of Gastroenterology, Paris, France, 11CHU St Etienne, Department of Gastroenterology, Saint-Etienne, France, 12Montfermeil Hospital, Department of Gastroenterology, Montfermeil, France, 13Charles Nicolle Hospital, Department of Gastroenterology, Rouen, France, 14CH Dron, Department of Gastroenterology, Tourcoing, France, 15Beaujon Hospital, Department of Gastroenterology, Paris, France, 16Montsouris Mutualist Institute, Department of Gastroenterology, Paris, France, 17Louis Mourier Hospital APHP, Department of Gastroenterology and Hepatology, Colombes, France, 18Nord Hospital, Department of Gastroenterology, Amiens, France, 19Saint-Louis Hospital, Department of Biostatistics, Paris, France, 20Saint-Louis Hospital, Department of Gastroenterology, Paris, France

DOP042

Most anti-TNF injectors are stored under suboptimal conditions at home

Authors:

M. de Jong*1, 2, M. Pierik1, 2, A. Peters3, M. Roemers4, F. van der Heijden5, V. Hilhorst6, A. van Tubergen7, 8

1Maastricht University Medical Centre+, Department of Internal Medicine, division of Gastroenterology and Hepatology, Maastricht, Netherlands, 2Maastricht University Medical Centre+, NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, 3Maastricht University Medical Centre+, Department of Internal Medicine, Maastricht, Netherlands, 4AntTail, Utrecht, Netherlands, 5MSD, Haarlem, Netherlands, 6Maastricht University Medical Centre+, Department of Clinical Pharmacy & Toxicology, Maastricht, Netherlands, 7Maastricht University Medical Centre+, Department of Internal Medicine, division of Rheumatology, Maastricht, Netherlands, 8Maastricht University Medical Centre+, CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands

DOP043

Nonadherence to anti-TNF therapy predicts clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre study

Authors:

M. van der Have*1, B. Oldenburg1, A. A. Kaptein2, J. M. Jansen3, R. C. Scheffer4, S. A. van Tuyl5, A. E. van der Meulen - de Jong6, M. Pierik7, P. D. Siersema1, M. G. van Oijen1, 8, H. H. Fidder1

1University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, 2Leiden University Medical Centre, Section Medical Psychology, Leiden, Netherlands, 3Onze Lieve Vrouwe Gasthuis, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, 4Jeroen Bosch Hospital, Department of Gastroenterology and Hepatology, ‘s Hertogenbosch , Netherlands, 5Diakonessenhuis, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, 6Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, 7Maastricht University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, Netherlands, 8Academic Medical Centre, Department of Medical Oncology, Amsterdam, Netherlands

DOP044

Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with inflammatory bowel disease

Authors:

K. Carlsen*1, 2, C. Jakobsen2, L. F. Hansen2, A. Paerregaard2, L. B. Riis3, P. S. Munkholm4, V. Wewer2

1Hvidovre Hospital, Paediatric, Hvidovre, Denmark, 2Hvidovre Hospital, Department of Paediatrics, Hvidovre, Denmark, 3Herlev Hospital, Department of Pathology, Herlev, Denmark, 4North Zealand Hospital, Department of Gastroenterology, Frederikssund, Denmark

DOP045

Self-administered telemedicine empowers paediatric and adolescent patients with Inflammatory Bowel Disease

Authors:

K. Carlsen*1, 2, C. Jakobsen2, L. F. Hansen2, A. Paerregaard2, T. Kallemose3, G. Houen4, L.B. Riis5, P. S. Munkholm6, V. Wewer2

1Hvidovre Hospital, Paediatric, Hvidovre, Denmark, 2Hvidovre Hospital, Department of Paediatrics, Hvidovre, Denmark, 3Hvidovre Hospital, Clinical Research Centre and Department of Orthopaedic, Hvidovre, Denmark, 4Statens Serum Institute, Department of Autoimmunology and Biomarkers, Copenhagen, Denmark, 5Herlev Hospital, Department of Pathology, Herlev, Denmark, 6North Zealand Hospital, Department of Gastroenterology, Frederikssund, Denmark

DOP046

Mid- to long-term stability and associated prognostic factors of adalimumab treatment for 1 189 patients with Crohns disease: a multicentre cohort study

Authors:

H. Tanaka*1, N. Kamata2, A. Yamada3, K. Endo4, T. Fujii5, T. Yoshino6, 7, T. Sugaya8, Y. Yokoyama9, S. Bamba10, J. Umeno11, Y. Yanai12, M. Ishii13, T. Kawaguchi14, S. Shinzaki15, Y. Toya16, T. Kobayashi17, M. Nojima18, T. Hibi17

1Sapporo Kosei General Hospital, IBD Centre, Sapporo, Japan, 2Osaka City University Graduate School of Medicine, Department of Gastroenterology, Osaka, Japan, 3Sakura Medical Centre, Toho University, Department of Internal Medicine, Chiba, Japan, 4Tohoku University Graduate School of Medicine, Division of Gastroenterology, Sendai, Japan, 5Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, 6Graduate School of Medicine, Kyoto University, Department of Gastroenterology and Hepatology, Kyoto, Japan, 7Tazuke Kofukai Medical Research Institute, Kitano Hospital, IBD Centre, Osaka, Japan, 8Dokkyo Medical University, Department of Gastroenterology, Tochigi, Japan, 9Hyogo College of Medicine, Division of Internal Medicine, Department of Inflammatory Bowel Disease, Hyogo, Japan, 10Shiga University of Medical Science, Division of Gastroenterology, Shiga, Japan, 11Kyushu University, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Fukuoka, Japan, 12Oita Red Cross Hospital, Department of Gastroenterology, Oita, Japan, 13Kawasaki Medical School, Department of Internal Medicine, Division of Gastroenterology, Kurashiki, Japan, 14Tokyo Yamate Medical Centre, Department of Internal Medicine, Division of IBD, Tokyo, Japan, 15Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Osaka, Japan, 16School of Medicine, Iwate Medial University, Division of Gastroenterology, Iwate, Japan, 17Kitasato University Kitasato Institute Hospital, Centre for Advanced IBD Research and Treatment, Tokyo, Japan, 18The Institute of Medical Science, The University of Tokyo, Centre for Translational Research, Tokyo, Japan

DOP047

PYRAMID registry: an observational study of adalimumab in Crohns disease—results at year 7

Authors:

G. D’Haens1, W. Reinisch*2, J. Satsangi3, E. Loftus Jr4, R. Panaccione5, H. Read6, M. Heinrich7, J. Petersson6, A.M. Robinson6

1Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands, 2Medical University of Vienna, Vienna, Austria, 3Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom, 4Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, Minnesota, United States, 5University of Calgary, Department of Medicine, Calgary, Canada, 6AbbVie Inc., North Chicago, Illinois, United States, 7AbbVie Deutschland, Ludwigshafen, Germany

DOP048

Delayed response to golimumab therapy: UC patient characteristics and long-term clinical outcome—post-hoc analyses from the PURSUIT programme

Authors:

J.-F. Colombel*1, W. Reinisch2, P. Gibson3, W. J. Sandborn4, B. Feagan5, S. Xu6, R. Strauss6, H. Zhang6, D. Tarabar7, Z. Hebzda8, P. Rutgeerts9, C. Marano6

1Mount Sinai, Icahn School of Medicine, New York, New York, United States, 2Universitätsklinik für Innere Medizin III and McMaster University, Vienna and Hamilton, Austria, 3Alfred Hospital, Melbourne, Australia, 4University of California San Diego, Division of Gastroenterology, La Jolla, California, United States, 5Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Ontario, Canada, 6Janssen R & D, LLC, Spring House, Pennsylvania, United States, 7Military Medical Academy, Department of Gastroenterology and Hepatology, Belgrade, Serbia, 8Military Hospital, Krakow, Poland, 9University Hospital Gasthuisberg, Department of Haematology, Leuven, Netherlands

DOP049

Efficacy and safety of golimumab induction 
for moderate-to-severe ulcerative colitis in 
the United Kingdom: results from the 
GO-COLITIS study

Authors:

C. Probert*1, D. R. Gaya2, P. J. Hamlin3, P. Irving4, S. Sebastian5, G. Gillespie6, H. Tate6, C. Wheeler6

1University of Liverpool, Liverpool, United Kingdom, 2Glasgow Royal Infirmary, Glasgow, United Kingdom, 3Leeds Teaching Hospitals Trust, Leeds, United Kingdom, 4Guy’s and St. Thomas’ Hospitals, London, United Kingdom, 5Hull & East Yorkshire NHS Trust, Hull, United Kingdom, 6MSD UK, Hoddesdon, United Kingdom

DOP050

The efficacy of vedolizumab by disease activity and prior tumour necrosis factor-alpha antagonist failure in patients with ulcerative colitis or Crohns disease: post-hoc analyses from the GEMINI 1 and GEMINI 2 studies

Authors:

G. D’Haens1, J.-F. Colombel*2, M. Dubinsky2, B. Abhyankar3, A. James3, K. Lasch4

1Academic Medical Centre, Amsterdam, Netherlands, 2Icahn School of Medicine at Mount Sinai Hospital, New York, New York, United States, 3Takeda Development Centre Europe Ltd, London, United Kingdom, 4Takeda Pharmaceuticals USA, Inc, Deerfield, Illinois, United States

DOP051

Response and remission rates with up to 3 years of vedolizumab treatment in patients with ulcerative colitis

Authors:

E.V. Loftus Jr1, J.-F. Colombel*2, A. Previtali3, M. Smyth3

1Mayo Clinic, Rochester, Minnesota, United States, 2Icahn School of Medicine at Mount Sinai Hospital, New York, New York, United States, 3Takeda Development Centre Europe Ltd, London, United Kingdom

DOP052

Ozanimod induces histological response and remission: results from the TOUCHSTONE study, a randomised, double-blind, placebo-controlled trial of ozanimod, an oral S1P receptor modulator, in moderate-to-severe ulcerative colitis

Authors:

W. Sandborn*1, B. Feagan2, G. D’Haens3, B. Levesque4, R. Pai5, S. Hanauer6, D. Wolf7, S. Vermeire8, S. Ghosh9, H. Smith10, M. Cravets10, P. Frohna10, S. Gujrathi10, R. Aranda10, A. Olson10

1University of California San Diego, Division of Gastroenterology, La Jolla, California, United States, 2Western University/Robarts Research Institute, Robarts Clinical Trials Inc., London, Ontario, Canada, 3Academic Medical Centre (AMC), Amsterdam, Netherlands, 4Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada, 5Mayo Clinic, Scottsdale, Arizona, United States, 6Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States, 7Atlanta Gastroenterology Associates, Atlanta, Georgia, United States, 8University of Leuven, Leuven, Belgium, 9University of Calgary, Calgary, Canada, 10Receptos, Inc., San Diego, California, States

DOP053

Effects of oral tofacitinib on patient-reported outcomes in patients with moderate-to-severe Crohns disease: results of 2 Phase 2b randomised placebo-controlled trials

Authors:

J. Panés*1, M. Moscariello2, E. Maller2, G. Chan2, W. Wang2, P. Healey3

1Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 2Pfizer Inc, Collegeville, United States, 3Pfizer Inc, Groton, Connecticut, United States

DOP054

Discrepancies between patient-reported outcomes, endoscopic, and histologic appearance in ulcerative colitis

Authors:

J.-F. Colombel*1, M. Keir2, A. Scherl2, R. Zhao2, G. de Hertogh3, W. Faubion4, T. Lu2

1Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, New York, United States, 2Genentech, South San Francisco, California, United States, 3Department of Imaging and Pathology, Catholic University of Leuven, Leuven, Belgium, 4Mayo Clinic Rochester, Department of Gastoenterology, Rochester, Minnesota, United States

DOP055

Azithromycin based therapy for induction of remission in mild to moderate active paediatric Crohns disease: the Multicentre azithromycin for Crohns disease AZCRO trial

Authors:

A. Levine*1, 2, J. Kierkuś3, M. Kori4, M. Sladek5, R. Sigall Boneh1, J. Escher6, E. Wine7, B. Yerushalmi8, J. Amil Dias9, R. Shaul10, A. Akriv11, D. Zucker11, D. Turner11, 12

1Wolfson Medical Centre, Paediatric Gastroenterology and Nutrition Unit, Tel-Aviv, Israel, 2Tel Aviv University, Tel-Aviv, Israel, 3The Children’s Memorial Health Institute, Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland, 4Kaplan Medical Centre, Paediatric Day Care Unit, Rehovot, Israel, 5Jagiellonian University Medical College, Department of Paediatrics, Gastroenterology and Nutrition, Cracow, Poland, 6Erasmus MC-Sophia Children’s Hospital, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, 7University of Alberta, Division of Paediatric Gastroenterology, Department of Paediatrics, Edmonton, Canada, 8Soroka Medical Centre, Ben Gurion University of the Negev, Paediatric Gastroenterology, Beer-Sheva, Israel, 9Hospital, S. João, Department of Paediatrics, Porto, Portugal, 10Meyer Children’s Hospital, Gastroenterology Unit, Haifa, Israel, 11The Hebrew University of Jerusalem, Jerusalem, Israel, 12Shaare Zedek Medical Centre, The Juliet Keidan Institute of Paediatric Gastroenterology & Nutrition, Jerusalem, Israel

DOP056

Pharmacokinetics and exposure-response relationships of golimumab in paediatric patients with moderate-to-severe ulcerative colitis: results from a multicentre open-label study

Authors:

O. J. Adedokun*1, D. Chan1, L. Padgett1, Y. Xu1, J. Hyams2, D. Turner3, Z. Xu1, H. Davis1, R. Strauss1

1Janssen R & D, LLC, Spring House, Pennsylvania, United States, 2Connecticut Children’s Medical Centre, Hartford, Connecticut, United States, 3The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Shaare Zedek Medical Centre, Jerusalem, Israel

DOP057

Tailored step-up approach results in beneficial long-term disease outcome in the prospective Belgian registry of paediatric Crohns disease (BELCRO)

Authors:

L. Wauters*1, F. Smets2, E. De Greef3, I. Hoffman4, P. Bontems5, S. Van Biervliet6, I. Paquot7, P. Alliet8, W. Arts9, M. De Vos10, P. Bossuyt11, J.-F. Rahier12, O. Dewit13, T. Moreels13, D. Franchimont14, V. Muls14, F. Fontaine15, E. Louis15, J.-C. Coche16, B. Hauser3, H. Peeters17, E. Van de Vijver18, F. Baert19, S. Vermeire1, G. Veereman3

1UZ Leuven, Gastroenterology and Hepatology, Leuven, Belgium, 2UCL St Luc, Paediatric Gastroenterology, Brussels, Belgium, 3UZ Brussel, Paediatric Gastroenterology, Brussels, Belgium, 4UZ Leuven, Paediatric Gastroenterology, Leuven, Belgium, 5HUDERF, Paediatric Gastroenterology, Brussels, Belgium, 6UZ Gent, Paediatric Gastroenterology, Ghent, Belgium, 7CHC Liège, Paediatric Gastroenterology, Liège, Belgium, 8Jessa ziekenhuis, Paediatric Gastroenterology, Hasselt, Belgium, 9ZOL Genk, Paediatric Gastroenterology, Genk, Belgium, 10UZ Gent, Gastroenterology, Ghent, Belgium, 11Imelda ziekenhuis, Gastroenterology, Bonheiden, Belgium, 12UCL Mont Godinne, Gastroenterology, Mont Godinne, Belgium, 13UCL St Luc, Gastroenterology, Brussels, Belgium, 14ULB Erasme, Gastroenterology, Brussels, Belgium, 15CHU Liège, Gastroenterology, Liège, Belgium, 16St Pierre, Gastroenterology, Ottignies, Belgium, 17ST Lucas, Gastroenterology, Ghent, Belgium, 18UZ Antwerpen, Paediatric Gastroenterology, Antwerp, Belgium, 19Heilig Hart Ziekenhuis, Gastroenterology, Roeselaere, Belgium

DOP058

Long-term avoidance of steroids associated with exclusive enteral nutrition as induction therapy in paediatric Crohns disease does not increase surgery, hospitalisations or biologics use: results of a propensity score-matched cohort analysis

Authors:

S. Basseri1, J. Connors2, A. Grant2, B. MacIntyre2, N. Giffin1, G. Mahdi2, A. Noble2, M. Rashid2, A. R. Otley2, J. Van Limbergen*2

1Dalhousie University, Halifax, Canada, 2IWK Health Centre, Halifax, Canada